Glaukos Corporation Common Stock (NY:GKOS)

237.82 -0.79 (-0.33%)

Delayed Quote Updated: 10:25 AM EST, Nov 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Glaukos (GKOS) Q1 2026 Earnings Transcript ↗

April 29, 2026

Glaukos (GKOS) Q1 2026 Earnings Transcript

Via The Motley Fool

Glaukos Corp (NYSE:GKOS) Shares Surge on Record Sales and Raised Guidance After Q1 Beat ↗

April 29, 2026

Via Chartmill

Glaukos Announces First Quarter 2026 Financial Results

April 29, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces the Release of its 2025 Sustainability Report

April 16, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules ↗

April 03, 2026

Via Chartmill

Glaukos Corp (NYSE:GKOS) Reports Record 2025 Sales but Shares Dip on Wider Loss, Conservative Outlook ↗

February 17, 2026

Via Chartmill

Glaukos Receives Permanent J-code for Epioxa™

April 15, 2026

From Glaukos Corporation

Via Business Wire

Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

April 08, 2026

From Glaukos Corporation

Via Business Wire

Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 06, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

March 19, 2026

From Glaukos Corporation

Via Business Wire

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗

February 19, 2026

Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗

February 19, 2026

This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.

Via The Motley Fool

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗

February 19, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.

Via The Motley Fool

Topics Regulatory Compliance

BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗

February 19, 2026

BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.

Via The Motley Fool

Topics Regulatory Compliance

Glaukos (GKOS) Q4 2025 Earnings Call Transcript ↗

February 17, 2026

Glaukos (GKOS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

February 17, 2026

From Glaukos Corporation

Via Business Wire

Director Sells GKOS 15,000 Shares for $1.9 Million ↗

January 31, 2026

This ophthalmic device maker, focused on glaucoma solutions, reported a notable insider sale after a challenging year for its stock.

Via The Motley Fool

Topics Regulatory Compliance

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

January 28, 2026

From Glaukos Corporation

Via Business Wire

Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

January 20, 2026

From Glaukos Corporation

Via Business Wire

These stocks are moving in today's after hours session ↗

January 13, 2026

Via Chartmill

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

January 13, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

December 16, 2025

From Glaukos Corporation

Via Business Wire

Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off ↗

November 06, 2025

Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off

Via The Motley Fool

Topics Regulatory Compliance

Glaukos Announces Participation in Upcoming Investor Conferences

November 03, 2025

From Glaukos Corporation

Via Business Wire

Why Glaukos Stock Zoomed Almost 14% Higher on Thursday ↗

October 30, 2025

The company's recent past featured robust growth, and it anticipates continued rises into the near future.

Via The Motley Fool

Glaukos (GKOS) Q3 2025 Earnings Call Transcript ↗

October 30, 2025

Glaukos (GKOS) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗

October 30, 2025

Via Benzinga

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

October 30, 2025

The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 30, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.